Oncology Exchange offers a forum for expert discussion of current and emerging trends in access to high-quality, evidence-based cancer care in Canada. It provides Canadian cancer care professionals with an exceptional venue to communicate advances in their field to other members of the multidisciplinary team, through original articles that showcase Canadian research and experience in diagnosis, treatment, symptom control, psychosocial and palliative care.
Oncology Exchange is published 4 times per year, and is circulated to 4600 oncology professionals, including medical oncologists, radiation oncologists, uro-oncologists, psycho-oncologists, palliative care specialists and oncology nurses.
We welcome letters, updates and comments on clinical organizational and political developments in Canadian cancer care, as well as original research articles and reviews. Authors of feature and review articles and commentaries receive an honorarium upon publication. The journal follows the International Committee of Medical Journal Editors Uniform Requirements for Manuscripts Submitted to Biomedical Journals, available at www.ICMJE.org. The following outlines requirements for submissions to Oncology Exchange.
- The article must be original; that is, has not been published elsewhere in the same form.
- Canadian authors are given preference.
- Feature articles can run up to 2000 words, with longer or shorter articles considered.
- Landmarks (research) commentaries can run up to 1200 words.
- All contributions should conform to conventional standards for evidence and value.
Please address correspondence to the attention
of Owen Dyer, Managing Editor,
by Email: email@example.com;
by Fax: (514) 397-0228
||Authors are encouraged to provide a brief outline of the proposed article in advance of submission. Acceptance of an article for publication is subject to scrutiny by the Editorial Advisory Board and/or members of the Expert Panel. All content is reviewed and approved by the Medical Editor in Chief, Dr. Jean Maroun. Articles specific to psycho-oncology and healthcare policy are reviewed and approved under the direction of the Editor for Psychosocial Oncology, Dr. Barry Bultz. Each article is also reviewed by at least one other reviewer, often a member of the Editorial Advisory Board or Expert Panel.
Submissions in all categories (see below) should:
- Be relevant to the practice of Canadian oncology professionals.
- Contain accurate and valid information.
- Present the information clearly and logically.
- Documents should be submitted by Email in Microsoft Word.
- Please include an abstract of 100-200 words.
- All references must be provided, as necessary, in standard biomedical style.
- Relevant illustrative material should be submitted with the article, including tables, charts, treatment algorithms, diagnostic visuals or photographs.
- All editing, copyediting, proofreading and layouts are the responsibility
- The Managing Editor of Oncology Exchange is assigned to edit and/or copyedit all submissions accepted for publication to conform to the standards set for the Journal.
- After the article has been edited and copyedited, it is returned to the author(s) for verification, response to queries and approval.
- The article is then reviewed and approved by the Editors in Chief and other members of the Advisory Board or Expert Panel. Any further queries, suggested changes or corrections are submitted to the author(s) for review.
- Once the manuscript is deemed final (i.e. has been approved by the authors and the Editors), the layout stage follows, with all graphic treatment produced by Parkhurst.
- Page proofs will be sent to authors FYI by email (as PDF files) or fax.
- PLEASE NOTE: The Editors of Oncology Exchange reserve the right to postpone publication of an accepted submission for space considerations.
||The copyright is transferred to Parkhurst when the article is accepted for publication. The copyright covers the exclusive rights to reproduce and distribute the article in any form. A pdf of the article may appear on the journal's open-access website, www.oncologyex.com.
Provides additional information, analysis or experience and Canadian
perspective about a critical issue raised in articles in the current
or past issues Oncology Exchange.
Topics: Usually pertain to care delivery,
organization and access issues.
Length: 300–1200 words including
Brief summary of a recently presented clinical trial (either at
a major conference or in the literature) with a commentary by a
leading Canadian expert, addressing clinical implications and next
steps in research.
Topics: Cancer of any disease site
or supportive care issue.
Length: Trial summary 200-300 words
(usually supplied by Parkhurst);
Commentary: 600-1500 words including
tables and references.
Review article, report of local practice or position paper.
Topics: Descriptions or critiques of
diagnostic or treatment modalities, supportive care practices, care
delivery strategies, research methodology and policy initiatives in
Length: Up to a maximum of 3000 words
including tables, figures and references.
Canadian consensus guideline.
or supportive care for cancer of any disease site.
Length: Up to 3000 words
Reports from Canadian meetings; may be a general report or highlight
specific aspects of the meeting.
Length: Up to 2000 words.